- Home
- TMC vs MLTX Comparison
TMC vs MLTX Comparison
Compare TMC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMC | MLTX |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TMC | MLTX |
|---|---|---|
| Price | $4.48 | $17.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $8.85 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $91.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $5.95 |
| 52 Week High | $11.35 | $62.75 |
Technical Indicators
Market Signals| Indicator | TMC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 42.77 |
| Support Level | $4.24 | $17.00 |
| Resistance Level | $4.89 | $19.24 |
| Average True Range (ATR) | 0.24 | 0.86 |
| MACD | 0.14 | -0.18 |
| Stochastic Oscillator | 80.52 | 33.17 |
Price Performance
Historical ComparisonAbout TMC TMC the metals company Inc.
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.